Gocovri (amantadine) has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for off episodes in people with Parkinson’s disease. Adamas Pharmaceuticals, which developed the therapy, announced its approval in the U.S. for Parkinson’s patients currently taking levodopa and/or carbidopa. Off episodes are periods during which levodopa-based treatments cease to be effective, causing Parkinson’s motor symptoms to return. This is the second indication for which Gocovri is now approved in…

You must be logged in to read/download the full post.